Evidence map›Paper›PMID 30570737›Full record

ArticleEndocrine2019

The novel myokine irisin: clinical implications and potential role as a biomarker for sarcopenia in postmenopausal women.

Hye-Sun Park, Hyun Chang Kim, Dongdong Zhang, Hyungseon Yeom, Sung-Kil Lim

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. State-of-the-art insights into myokines as biomarkers of sarcopenia: a literature review.International journal of physiology, pathophysiology and pharmacology · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hye-Sun ParkDepartment of Endocrinology, H Plus Yangji Hospital, Seoul, Republic of Korea.
Hyun Chang KimDepartment of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Dongdong ZhangBrain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea.
Hyungseon YeomDepartment of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Sung-Kil LimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. lsk@yuhs.ac.

Funding

National Research Foundation of Korea NRF-2014R1A2A1A11053818
6 · The paper itself

Abstract

purposeTo clarify the association of circulating irisin with muscle, liver and bone, and to evaluate irisin as a biomarker for sarcopenia in postmenopausal women.

methodsQuadriceps cross-sectional area (QcCSA), bone mineral density (BMD), liver attenuation (measured in Hounsfield units (HU)) were assessed using quantitative computed tomography in 153 postmenopausal women, mean age of 72.20 ± 5.96 years. Muscle strength and physical performance were evaluated by handgrip test and short physical performance battery, respectively. Serum irisin was measured by an enzyme-linked immunosorbent assay kit. In addition, 147 young women were recruited as a reference group to define cut-off values for sarcopenia.

resultsCirculating irisin was positively correlated with QcCSA/body weight (BW) and liver HU even after adjusting for multiple covariates, and the serum level was significantly lower in the sarcopenia group (QcCSA/BW<-2SD of the mean values for young women) than in the presarcopenia (-2SD≤QcCSA/BW<-1SD) or control groups (1SD≤QcCSA/BW<2SD). Logistic regression models showed that the relationship between circulating irisin and prevalence of sarcopenia remained significant after adjusting for confounding factors (per 1.0 ng/mL decrease of irisin, odds-ratio = 1.95, 95% confidence interval 1.33-2.87, p-value = 0.001).

conclusionsIn postmenopausal women, serum irisin may be used as a biomarker for sarcopenia, and we showed the potential for the development of irisin-based early screening and staging tool for sarcopenia.

Indexed as

AgedBiomarkersBody CompositionBone DensityFemaleFibronectinsHand StrengthHumansMuscle, SkeletalPostmenopauseSarcopeniaTomography, X-Ray ComputedBiomarkersFibronectinsFNDC5 protein, humanAgingIrisinSarcopeniaScreening

Identifiers

PMID30570737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.